Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Addictive Behaviors|April 2, 2021
Youth use of e-cigarettes: Does dependence vary by device type?Alayna P Tackett, Emily T Hébert, Caitlin E Smith, et al.
Molecular Autism|November 3, 2024
Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile X syndromeJordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett, et al.
Research Square|July 1, 2024
Auditory N1 event-related potential amplitude is predictive of serum concentration of BPN14770 in fragile x syndromeJordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett, et al.
Translational Psychiatry|August 28, 2025
ROC Analysis of Biomarker Combinations in Fragile X Syndrome-Specific Clinical Trials: Evaluating Treatment Efficacy via Exploratory BiomarkersJordan E Norris, Elizabeth M Berry-Kravis, Mark D Harnett, et al.
Medrxiv : the Preprint Server for Health Sciences|February 20, 2025
Auditory steady-state response deficits in Fragile X Syndrome implicate deficits in stimulus representation maintenance and GABAergic modulationJordan E Norris, Lisa A De Stefano, Walker S McKinney, et al.
Biorxiv : the Preprint Server for Biology|April 1, 2025
A human electrophysiological biomarker of Fragile X Syndrome is shared in V1 of Fmr1 KO mice and caused by loss of FMRP in cortical excitatory neuronsSara S Kornfeld-Sylla, Cigdem Gelegen, Jordan E Norris, et al.
Nature Communications|February 9, 2026
A human electrophysiological signature of Fragile X pathophysiology is shared in V1 of Fmr1-/y miceSara S Kornfeld-Sylla, Cigdem Gelegen, Jordan E Norris, et al.
Journal of Child and Adolescent Psychopharmacology|December 9, 2024
Results from a Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Crossover Trial of Lovastatin or Minocycline in Fragile X SyndromeWalker S McKinney, Lauren M Schmitt, Lisa A De Stefano, et al.
Pageof 2